Tepotinib is recommended by NICE to treat advanced non-small-cell lung cancer with METex14 skipping alterations in adults.- Merck KGaA
Why the committee made these recommendations ? Standard care for advanced METex14 skipping NSCLC is usually chemoimmunotherapy. People have different treatments depending on their PD-L1 tumour proportion score and whether they have squamous or non-squamous NSCLC. Clinical trial evidence suggests a clinical benefit for tepotinib. It has been indirectly compared with other treatments in 2 ways, but the results of both are uncertain. Tepotinib meets NICE’s criteria to be considered a life-extending drug at the end of life for people who have had previous treatment, but not for people who have not had previous treatment. For both groups, the cost-effectiveness estimates are within the range NICE normally considers an acceptable use of NHS resources. So, tepotinib is recommended.